Compare ALGN & PEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ALGN | PEN |
|---|---|---|
| Founded | 1997 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.7B | 12.8B |
| IPO Year | 2000 | 2015 |
| Metric | ALGN | PEN |
|---|---|---|
| Price | $176.67 | $326.21 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 12 | 16 |
| Target Price | $199.82 | ★ $360.14 |
| AVG Volume (30 Days) | ★ 956.9K | 476.6K |
| Earning Date | 04-29-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 0.53 | ★ 1155.56 |
| EPS | ★ 5.65 | 4.52 |
| Revenue | $387,126,000.00 | ★ $1,403,665,000.00 |
| Revenue This Year | $5.78 | $14.34 |
| Revenue Next Year | $4.62 | $13.71 |
| P/E Ratio | ★ $30.94 | $72.14 |
| Revenue Growth | ★ 23.95 | 17.50 |
| 52 Week Low | $122.00 | $221.26 |
| 52 Week High | $208.31 | $362.41 |
| Indicator | ALGN | PEN |
|---|---|---|
| Relative Strength Index (RSI) | 45.45 | 39.34 |
| Support Level | $175.35 | $302.19 |
| Resistance Level | $183.34 | $335.61 |
| Average True Range (ATR) | 6.17 | 2.93 |
| MACD | -1.50 | -0.31 |
| Stochastic Oscillator | 29.42 | 18.33 |
Align Technology is the leading manufacturer of clear aligners. Invisalign, its main product, was approved by the Food and Drug Administration in 1998 and has since dominated, controlling over 90% of the market. Invisalign can treat roughly 90% of all malocclusion cases (misaligned teeth), and there are over 230,000 Invisalign-trained dentists and orthodontists. In 2022, Invisalign treated over 2 million cases, or roughly 10% of all orthodontic cases for the year, and it has treated over 14 million patients since its launch. Align also sells intraoral scanners under the brand iTero, which captures digital impressions of patients' teeth and illustrates treatment plans. Over 85% of Invisalign cases are submitted by digital scans, and iTero scans make up over half of these scans.
Penumbra Inc is a thrombectomy company focused on developing technologies for challenging medical conditions such as ischemic stroke, venous thromboembolism (including pulmonary embolism), and acute limb ischemia. Its portfolio includes Computer-Assisted Vacuum Thrombectomy (CAVT), which is designed to remove blood clots throughout the body. The company offers products such as the Artemis Neuro Evacuation Device (used for surgical removal of fluid and tissue from the ventricles and cerebrum), Indigo System, Penumbra System Reperfusion Catheter, LANTERN Delivery Microcatheter, Penumbra Smart Coil, and ACE Reperfusion Catheters, among others. The company generates maximum revenue from the sale of its products in the United States, followed by international markets.